Why the study?
Oxaliplatin-induced peripheral neuropathy is a chronic, debilitating late effect, prompting investigation of neurofilament light chain as a marker of neuronal damage in vitro and in vivo.
Does oxaliplatin exposure increase Neurofilament light chain (NfL) levels and correlate with peripheral neuropathy symptoms in patients with colorectal cancer?
Does oxaliplatin exposure increase Neurofilament light chain (NfL) levels and correlate with peripheral neuropathy symptoms in patients with colorectal cancer?
NfL changes may track oxaliplatin-induced neuropathy symptoms; leaves open prospective validation before guiding dosing or monitoring.
PURPOSE: Oxaliplatin-induced peripheral neuropathy (OIPN) is a chronic, debilitating late effect following oxaliplatin treatment. Neurofilament light chain (NfL) is a structural protein found in nerve axons that was investigated upon oxaliplatin exposure in vitro and in vivo correlated to symptoms of OIPN in colorectal cancer patients receiving oxaliplatin. METHODS: Human sensory neurons, derived from induced pluripotent stem cells, were exposed to clinically relevant concentrations of oxaliplatin in vitro, with NfL concentrations measured in the cell medium. The prospective clinical study included patients with colorectal cancer undergoing chemotherapy therapy with or without oxaliplatin. Possible OIPN was defined as bilateral presence of numbness and/or presence of pricking sensations in the feet documented in an interview at the time of blood sampling prior to, 3, and 6 months after initiating treatment. RESULTS: Oxaliplatin exposure led to a dose-dependent NfL increase in vitro. In the clinical cohort of 30 patients (18 in the oxaliplatin group), NfL levels rose at 3 and 6 months compared to controls. NfL level changes correlated to OIPN symptoms at the 6-month timepoint (rho 0.81, p < 0.001). However, the interindividual variation was substantial, and most patients showed only a minor increase in NfL. CONCLUSION: Both in vitro and clinical data indicate that oxaliplatin exposure results in elevated NfL levels. Further prospective studies are needed to evaluate NfL as an early biomarker for OIPN, specifically focusing on the timing of blood sampling during chemotherapy treatment to enable the timely reduction of oxaliplatin.
No takes yet. Share an insight, caveat, or question.
Gehr et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: